COPD Clinical Trials
In order to advance the development of new treatments for chronic obstructive pulmonary disease (COPD), Mount Sinai’s Division of Pulmonary, Critical Care, and Sleep Medicine is conducting a number of clinical trials. These studies seek to provide patients with relief from COPD symptoms, which include frequent coughing, shortness of breath, and chest tightness. They also aim to reduce the frequency and severity of COPD exacerbations, thereby slowing the progression of the disease.
Mount Sinai’s current COPD clinical trials include the following:
- Study to assess tiotropium bromide delivered via the HandiHaler in COPD patients recovering from hospitalization for an exacerbation: The objective of this trial is to investigate the safety and efficacy of a medication called tiotropium bromide (18 mcg), which is inhaled using the HandiHaler delivery system. The trial is designed for patients recovering from recent hospitalizations for an acute exacerbation of COPD. (a randomized, placebo-controlled, double-blind, parallel group, multicenter study)
- Study to evaluate the effect of Roflumilast on exacerbation rate in COPD patients treated with a fixed-dose combination of long-acting beta agonist and inhaled corticosteroid (LABA/ICS): The objective of this study is to assess any increased benefit of the medication Roflumilast (500 mcg) when added to a patient’s regimen of existing prescriptions, such as Advair or Symbicort. The trial is seeking to reduce the severity and frequency of exacerbations in patients with severe or very severe COPD. (a 52-week, randomized, placebo-controlled, double-blind, parallel group study)
Any patients interested in more information about COPD studies conducted at Mount Sinai are welcome to contact clinical research coordinator Ghimja Berhanu.
Last Updated: January 9, 2014
To Make an Appointment:
5 East 98th Street
New York NY 10029